NASDAQ:NBEV

NewAge Stock Forecast, Price & News

$2.53
+0.06 (+2.43 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.45
$2.55
50-Day Range
$1.97
$2.82
52-Week Range
$1.42
$4.55
Volume807,510 shs
Average Volume1.12 million shs
Market Capitalization$342.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
30 days | 90 days | 365 days | Advanced Chart
Receive NBEV News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAge and its competitors with MarketBeat's FREE daily newsletter.


NewAge logo

About NewAge

NewAge, Inc. develops, markets, sells, and distributes healthy products in the United States, Japan, China, and internationally. The company operates in two segments, Direct / Social Selling and Direct Store. It provides health and wellness, energy drink, essential oil and anti-aging skincare, cosmetic, beverage, snacks, water and air filtration, and personal care products, as well as weight management, nutritional supplement, nutraceutical, and slenderiize products; diagnostic products, such as DNA testing and diagnostic kits and products; and CBD products. The company offers its products under the Tahitian Noni, LIMU, Zennoa, LIMU Blue Frog, Hiro Natural, TeMana, Lucim, Reviive, Puritii, and MaVie brands. It sells its products directly to customers, as well as through distributors, e-commerce sites, and direct-store-delivery systems. The company was formerly known as New Age Beverages Corporation and changed its name to NewAge, Inc. in July 2020. NewAge, Inc. was incorporated in 2010 and is headquartered in Denver, Colorado.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.19 out of 5 stars

Consumer Staples Sector

137th out of 311 stocks

Malt Beverages Industry

8th out of 14 stocks

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











NewAge (NASDAQ:NBEV) Frequently Asked Questions

Is NewAge a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NewAge in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NewAge stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBEV, but not buy additional shares or sell existing shares.
View analyst ratings for NewAge
or view top-rated stocks.

What stocks does MarketBeat like better than NewAge?

Wall Street analysts have given NewAge a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NewAge wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NewAge's next earnings date?

NewAge is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for NewAge
.

How were NewAge's earnings last quarter?

NewAge, Inc. (NASDAQ:NBEV) announced its quarterly earnings data on Monday, May, 10th. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.12. NewAge had a negative net margin of 13.33% and a negative trailing twelve-month return on equity of 29.16%.
View NewAge's earnings history
.

How has NewAge's stock price been impacted by Coronavirus (COVID-19)?

NewAge's stock was trading at $1.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NBEV stock has increased by 47.1% and is now trading at $2.53.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NBEV?

1 brokerages have issued twelve-month target prices for NewAge's stock. Their forecasts range from $5.00 to $5.00. On average, they expect NewAge's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 97.6% from the stock's current price.
View analysts' price targets for NewAge
or view top-rated stocks among Wall Street analysts.

Who are NewAge's key executives?

NewAge's management team includes the following people:
  • Mr. Brent David Willis, CEO & Director (Age 60, Pay $1.02M)
  • Mr. Gregory A. Gould CPA, CPA, Chief Financial Officer (Age 55, Pay $585.82k)
  • Mr. Mark H. Wilson, Group Pres (Age 56)
  • Mr. Riley Timmer, VP of Investor Relations
  • Mr. Michael Cunningham, Sr. VP of Sales
  • Ms. Carin Casso Reinhardt, Chief People Officer
  • Mr. Jay Barrow, Head of Brand
  • Mr. Kelly Olsen, Chief Commercial Officer (Age 66)
  • Dr. Randy L. Looper, Pres of New Age Health Sciences Divisions
  • Dr. Gerald M. Haase M.D., Chief Medical Officer

Who are some of NewAge's key competitors?

What other stocks do shareholders of NewAge own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewAge investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), Cronos Group (CRON), Advanced Micro Devices (AMD), Micron Technology (MU), NIO (NIO), BHP Group (BHP), (APHA) and General Electric (GE).

What is NewAge's stock symbol?

NewAge trades on the NASDAQ under the ticker symbol "NBEV."

Who are NewAge's major shareholders?

NewAge's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.52%), Geode Capital Management LLC (1.29%), Altium Capital Management LP (0.88%), Millennium Management LLC (0.82%), Northern Trust Corp (0.75%) and Dimensional Fund Advisors LP (0.60%). Company insiders that own NewAge stock include Brent D Willis and Timothy J Haas.
View institutional ownership trends for NewAge
.

Which institutional investors are selling NewAge stock?

NBEV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Thrivent Financial for Lutherans, New York State Common Retirement Fund, Perritt Capital Management Inc., Royal Bank of Canada, Nuveen Asset Management LLC, and Credit Suisse AG.
View insider buying and selling activity for NewAge
or view top insider-selling stocks.

Which institutional investors are buying NewAge stock?

NBEV stock was acquired by a variety of institutional investors in the last quarter, including Altium Capital Management LP, BlackRock Inc., Millennium Management LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC, Davy Global Fund Management Ltd, Renaissance Technologies LLC, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for NewAge
or or view top insider-buying stocks.

How do I buy shares of NewAge?

Shares of NBEV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NewAge's stock price today?

One share of NBEV stock can currently be purchased for approximately $2.53.

How much money does NewAge make?

NewAge has a market capitalization of $342.74 million and generates $279.47 million in revenue each year. The company earns $-39,340,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does NewAge have?

NewAge employs 1,127 workers across the globe.

What is NewAge's official website?

The official website for NewAge is newagebev.us.

Where are NewAge's headquarters?

NewAge is headquartered at 2420 17TH STREET SUITE 220, DENVER CO, 80202.

How can I contact NewAge?

NewAge's mailing address is 2420 17TH STREET SUITE 220, DENVER CO, 80202. The company can be reached via phone at 303-289-8655 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.